SYNOPSIS Components of the blood fibrinolytic system were measured in 18 patients with hepatic cirrhosis, in two patients with acute hepatic necrosis, and in 10 patients with hepatic metastases. The frequency of an elevation of plasminogen activator and a reduction in plasminogen in hepatic cirrhosis has been confirmed. Patients with compensated cirrhosis had low levels of the serum inhibitor of plasminogen activation while those with severe hepatic insufficiency or coma due to cirrhosis or hepatic necrosis had elevated levels. The presence of hepatic metastases was associated with reduced plasminogen activator levels and an increase in the fibrinogen concentration.
Human blood contains an enzyme system which, on activation, results in the formation of plasmin, an endopeptidase activity at near neutiality. An integral component of this system (the fibrinolytic enzyme system) is plasminogen, a ,-globulin, which is converted to plasmin under the influence of activators. The number and source of plasminogen activators is uncertain, but there is substantial evidence that vascular endothelial cells are at least one source (Todd, 1958) . Inhibitors probably have an important regulating role in the fibrinolytic system. Antiplasmins, principally a2-macroglobulin and aL-antitrypsin, are present in considerable quantities in blood, and recently it has been shown that the coagulation of blood is associated with the appearance of an inhibitor of plasminogen activation (Bennett, 1967; Helle, 1968; Bennett, 1970) .
Abnormal blood fibrinolytic activity in patients with hepatic cirrhosis has been recognized since the earlier years of this century when Goodpasture (1914) reported that the clots formed from blood obtained from patients with cirrhosis underwent lysis more rapidly than did clots from the blood of control subjects. This finding has been confirmed repeatedly (Ratnoff, 1949; Kwaan, McFadzean, and Cook, 1956; Bergstrom, Blomback, and Kleen, 1960; Grossi, Moreno, and Rousselot, 1961) .
Ratnoff (1949) observed that rapid lysis of plasma clots occurred also in patients with hepatic damage other than cirrhosis, but not in obstructive jaundice or acute hepatitis. The mechanism of the increased Received for publication 15 April 1971. blood fibrinolytic activity in portal cirrhosis has not been established; impaired hepatic clearance of plasminogen activator or a decrease in the level of inhibitors of fibrinolysis are the principal alternative hypotheses.
We report our findings on the measurements of the major known components of the fibrinolytic enzyme system in the blood of patients with hepatic cirrhosis, acute necrosis, and malignant metastases.
Methods and Patients

PLASMINOGEN ACTIVATOR
Plasminogen activator was assessed by performing euglobulin clot lysis times by the method of Nilsson and Olow (1962) . The results were expressed by plotting the lysis times logarithmically against units of fibrinolytic activity (Sherry, Lindemeyer, Fletcher, and Alkjaersig, 1959) Alkjaersig, Fletcher, and Sherry (1959a) and the results expressed in Sherry units (Alkjaersig, Fletcher, and Sherry, 1959b) .
SERUM INHIBITOR
Serum inhibitor of plasminogen activation was measured using a standard clot system as described by Bennett (1967 (Ogston and Ogston, 1966) of the method of Ratnoff and Menzie (1951) .
PATIENTS
Thirty patients with liver disease were studied. Their diagnosis was established by history, examination, and laboratory findings aided, in some patients, by the histological appearances of tissue obtained at biopsy or necropsy. The diagnosis was confirmed subsequently at operation or necropsy in a number of patients.
Blood samples were obtained before the start of specific drug therapy or surgery, and before blood replacement.
NORMAL VALUES
Control plasminogen activator levels were obtained from healthy subjects or patients convalescent from a variety of minor disorders. All had been at rest in bed for at least 12 hours.
The control values for plasminogen, fibrinogen, serum inhibitor of plasminogen activation, and plasma antiplasmin activity were obtained from healthy volunteers aged between 35 and 75. All were free from symptoms of physical disease and had a Westergren erythrocyte sedimentation rate in the normal range (Hilder and Gunz, 1964) .
Results
NORMAL VALUES
Control levels, means, and standard deviations for plasminogen activator, plasminogen, fibrinogen, activation inhibitor, and antiplasmin activity are shown in Table I (Table IL) . In the patient D. Ogston, N. B. Bennett, and C. M. Ogston in whom it was assayed the serum inhibitor of plasminogen activation was greatly increased as in the patients with cirrhosis and severe hepatic failure.
HEPATIC METASTASES
The majority of the 10 patients with liver metastases had reduced plasminogen activator levels (Table  III) : most had a moderate increase in the plasma fibrinogen concentration. The plasminogen level was within the normal range in five patients and reduced in five, but only a single patient had a very low level. The inhibitor assays were within the normal range apart from two patients with an elevated level of the inhibitoi of plasminogen activation.
Discussion
There is general agreement that plasma fibrinolytic activity is increased in patients with portal cirrhosis. The mechanism, however, remains in debate. A high level of plasminogen activator in cirrhotic tissue was shown by Astrup, Rasmussen, Amery, and Poulsen (1960) and its relation to increased plasma levels postulated. There are experimental data that the normal liver clears plasminogen activator from the plasma (Grossi, Rousselot, and Panke, 1962;  Fletcher, Biederman, Moore, Alkjaersig, and Sherry, 1964 (Purcell and Phillips, 1963; O'Connell, Grossi, and Rousselot, 1964; Tytgat, Collen, de Vreker, and Verstraete, 1968) and have related this finding to the increased fibrinolysis in hepatic cirrhosis. In this context it is relevant that Mattii, Ambrus, Sokal, and Mink (1964) found that isolated rat liver produced antiplasmin, but not plasminogen activators or plasminogen.
Our results again point to the frequency of increased levels of circulating plasminogen activator in patients with hepatic cirrhosis and, in keeping with most other investigators (Purcell and Phillips, 1963; Fletcher et al, 1964) , confirm that the plasma plasminogen level is often reduced. In contrast, Das and Cash (1969) did not find a reduced mean plasminogen level in their patients; those patients had probably less advanced and severe cirrhosis. The reduction in the plasminogen concentration may be due to its consumption secondary to the systematic increase in activator level consequent on its impaired hepatic clearance (Fletcher et al, 1964) ; this view is supported by our finding that the use of the fibrinolytic inhibitor, epsilon-aminocaproic acid, was followed by an increase in the plasminogen level. Alternatively the low plasminogen levels may be the result of disseminated intravascular coagulation which can occur in cirrhosis (Bergstrom et al, 1960; Zetterqvist and von Franken, 1963; Johansson, 1964; Blomback, Carlson, Franzen, and Zetterqvist, 1966) and which has been shown to be a prominent mechanism in acute hepatic necrosis (Rake, Flute, Pannell, and Williams, 1970) . A further possibility is that the lowered plasminogen levels could result from impaired hepatic synthesis, but evidence points to eosinophil granulocytes rather than the liveras the site of plasminogen synthesis in man (Barnhart and Riddle, 1963) .
We have found that some patients with portal cirrhosis have decreased antiplasmin levels. The findings in respect of the other inhibitors measured, the serum inhibitor of plasminogen activation, are of interest; this inhibitor is distinct from antiplasmins and plasma antiurokinase activity and levels in hepatic disease have not been reported. They appear to be reduced in compensated cirrhosis, but elevated in hepatic failure. A possible explanation is that the plasma precursor of this inhibitor is released from injured cells: a rise has also been observed following myocardial infarction and surgical trauma (Bennett, Ogston, and Ogston, 1967) . The significance of the alterations in the serum inhibitor of plasminogen activation in relation to the clinical features of cirrhosis is obscure in the absence of an understanding of the role of this and other inhibitors in the control of fibrinolytic activity in vivo.
Decreased fibrinolysis has been reported in primary carcinoma of the liver associated with the appearance in the blood of an antiactivator, but not antiplasmin activity (Kwaan, Lo, and McFadzean, 1959) . Fletcher and his associates (1964) noted that patients with metastatic carcinomatous involvement of the liver did not exhibit enhanced plasminogen activator levels after the administration of nicotinic acid. A number of patients in the present study with hepatic metastases had reduced plasminogen levels in association with low activator levels. The explanation is not apparent, but the reduced plasminogen levels may be secondary to disseminated intravascular coagulation which may occur in disseminated cancer (Merskey, Johnson, Kleiner, and Wohl, 1967) .
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